Lung cancer remains a global challenge due to high morbidity and mortality rates and poor response to treatment, and there are still no effective strategies to solve it. The bispecific antibody (BsAb) is a novel antibody, which can target two different antigens and mediate specific killing effects by selectively redirecting effector cells to the target cells. In this study, we combined two BsAbs to achieve a dual-target therapy strategy of EpCAM+ and MUC-1+ with high affinity and specificity. The results showed that the combination of two BsAbs against EpCAM and MUC-1 could inhibit the growth of lung cancer more effectively in cell lines and primary tumors. The superior antitumor effect of two BsAbs could be attributable to enhanced CTL and increased production of type I IFNs. At the same time, the combination of EpCAM/CD3 BsAb and MUC-1/CD3 BsAb significantly regulated T population in the TDLNs. Therefore, we have found a potential immunotherapeutic strategy, which was the combination therapy with EpCAM/CD3 BsAb and MUC-1/CD3 BsAb for the treatment of non-small cell lung cancer.

中文翻译：

---

EpCAM/CD3 BsAb 和 MUC-1/CD3 BsAb 联合治疗通过 T 细胞过继性免疫治疗在肺癌中引发抗肿瘤免疫。

肺癌由于发病率和死亡率高，治疗反应差，仍然是一个全球性的挑战，目前还没有有效的策略来解决它。双特异性抗体（BsAb）是一种新型抗体，它可以靶向两种不同的抗原，并通过选择性地将效应细胞重定向到靶细胞来介导特异性杀伤作用。在本研究中，我们结合了两种 BsAb，实现了 EpCAM+ 和 MUC-1+ 的双靶点治疗策略，具有高亲和力和特异性。结果表明，两种抗 EpCAM 和 MUC-1 的 BsAb 联合使用可以更有效地抑制肺癌在细胞系和原发性肿瘤中的生长。两种 BsAb 的卓越抗肿瘤作用可归因于 CTL 增强和 I 型 IFN 产量增加。同时，EpCAM/CD3 BsAb 和 MUC-1/CD3 BsAb 的组合显着调节了 TDLNs 中的 T 群体。因此，我们发现了一种潜在的免疫治疗策略，即与EpCAM/CD3 BsAb和MUC-1/CD3 BsAb联合治疗非小细胞肺癌。